Clinical Challenges: Test Your Knowledge on Recent Advances in DLBCL

Derick Alison
Derick Alison
1 Min Read

Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow.

This three-question quiz will test one aspect from each article in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory disease setting; adoption of the first-line regimen of polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP); and the prophylaxis and treatment of central nervous system (CNS) relapse.

Correct answers and explanations appear after completing the quiz.

  • Leah Lawrence is a freelance health writer and editor based in Delaware.

Source link

Share this Article
Leave a comment
adbanner